Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $68.29 in the prior trading day, Dexcom Inc (NASDAQ: DXCM) closed at $67.32, down -1.42%. In other words, the price has decreased by -$1.42 from its previous closing price. On the day, 3.21 million shares were traded. DXCM stock price reached its highest trading level at $68.4 during the session, while it also had its lowest trading level at $66.31.
Ratios:
Our goal is to gain a better understanding of DXCM by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.20 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 41.71. For the most recent quarter (mrq), Quick Ratio is recorded 1.28 and its Current Ratio is at 1.47. In the meantime, Its Debt-to-Equity ratio is 1.23 whereas as Long-Term Debt/Eq ratio is at 0.65.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Redburn Atlantic on February 03, 2025, Upgraded its rating to Buy and sets its target price to $115 from $85 previously.
On January 16, 2025, Robert W. Baird Upgraded its rating to Outperform which previously was Neutral and also upped its target price recommendation from $86 to $104.
Robert W. Baird Downgraded its Outperform to Neutral on July 26, 2024, whereas the target price for the stock was revised from $161 to $80.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 17 ’25 when Heller Bridgette P sold 352 shares for $70.33 per share. The transaction valued at 24,756 led to the insider holds 22,997 shares of the business.
Heller Bridgette P bought 352 shares of DXCM for $24,756 on Mar 17 ’25. On Mar 12 ’25, another insider, Leach Jacob Steven, who serves as the EVP, Chief Operating Officer of the company, sold 14,076 shares for $70.38 each. As a result, the insider received 990,670 and left with 313,497 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 26396643328 and an Enterprise Value of 26321172480. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 47.26, and their Forward P/E ratio for the next fiscal year is 27.17. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.07. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.52 while its Price-to-Book (P/B) ratio in mrq is 12.51. Its current Enterprise Value per Revenue stands at 6.526 whereas that against EBITDA is 32.189.
Stock Price History:
The Beta on a monthly basis for DXCM is 1.50, which has changed by -0.51397014 over the last 52 weeks, in comparison to a change of 0.08089435 over the same period for the S&P500. Over the past 52 weeks, DXCM has reached a high of $141.99, while it has fallen to a 52-week low of $62.34. The 50-Day Moving Average of the stock is -17.47%, while the 200-Day Moving Average is calculated to be -16.97%.
Shares Statistics:
The stock has traded on average 3.94M shares per day over the past 3-months and 4169440 shares per day over the last 10 days, according to various share statistics. A total of 390.70M shares are outstanding, with a floating share count of 385.26M. Insiders hold about 1.41% of the company’s shares, while institutions hold 92.86% stake in the company. Shares short for DXCM as of 1741910400 were 11474317 with a Short Ratio of 2.92, compared to 1739491200 on 9481584. Therefore, it implies a Short% of Shares Outstanding of 11474317 and a Short% of Float of 3.32.
